Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in NSCLC with Brain Metastases
NCT00372775Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2007
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Progression-Free Survival at 1 year. Started Mar 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00372775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372775.